Personalized and Precision Medicine Journal

Abstract The ability of immunotherapy to treat ovarian cancer is currently limited, however evaluating sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may enhance this ability. These indicators include the number of tumor mutations, PD-L1, tumor-infiltrating lymphocytes, a lack of homologous recombination, and intratumoral heterogeneity of neoantigens. The use of these indicators to choose the best candidates for ovarian cancer treatment is one of the future directions. In addition to reviewing innovative treatments and study designs including tumor biomarkers that improve the chances of immunotherapy success in ovarian cancer, this paper also analyzes the function of immunotherapy in ovarian cancer.